SV Life Sciences Fund IV (Exited Investments)

SVLSF IV closed in February 2007 with total commitments of $550 million (plus $22 million of co-investments committed by partners and individuals affiliated with SVLS).

As at 31 March 2010 the Fund had invested $316 million in 37 portfolio companies.

To go to individual portfolio companies websites please click on company logo.

RespiVert: UK - Exited

First Investment: 2007 - Start Up

RespiVert is a discovery company focused on Chronic obstructive pulmonary disease ('COPD') and severe asthma. The company’s goal is to develop novel inhaled and intranasal drugs for respiratory disorders with high unmet medical need and high commercial potential based on novel insights on biology and chemistry.

---

X2-Pharma: Germany - Exited

First investment: 2008 - Seed

X2-Pharma is a biopharmaceutical company dedicated to the discovery and development of small molecule pharmaceuticals for the treatment of inflammatory diseases.

---